Summary
Fast-absorbed and short-acting dihydropyridines (e.g., nifedipine capsules) cause intermittent hemodynamic effects associated with sympathetic hyperactivity. In contrast, long-acting dihydropyridines, such as nifedipine GITS and amlodipine, provide, during chronic treatment, stable hemodynamic effects with little or no activation of the sympathetic nervous system. This markedly different pattern of hemodynamic changes may explain why the short-acting drugs cause little to no regression of left ventricular hypertrophy, may make angina worse, and may negatively affect cardiac outcome, whereas the long-acting drugs decrease LV mass as anticipated from the fall in blood pressure and, at least in stable coronary artery disease, produce an outcome comparable with beta-blockers. In hypertension, beta-blocker treatment appears to be associated with a short fall in positive outcome, perhaps in part related to increased rates of sudden death. Such an adverse outcome may also be due to sympathetic hyperactivity, possibly during treatment via cardiac alpha-receptors, but also during the common short periods of noncompliance due to actual increased sympathetic responses. For both drug classes, we suggest that long-acting agents be considered, providing therapeutic coverage well beyond the normal dosing interval.
References
Jaglal SB, Tu JV, Naylor CD. Higher in-hospital mortality in female patients following coronary artery bypass surgery: A population-based study. Clin Invest Med 1995;18: 99–107.
MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: Principal results. Br Med J 1992;304:405–412.
Stone PH, Muller JE, Turi ZG, et al. Efficacy of nifedipine therapy in patients with refractory angina pectoris: Significance of the presence of coronary vasospasm. Am Heart J 1983;106:644–652.
Boden WE, Korr KS, Bough EW. Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris. JAMA 1985:253:1131–1135.
Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. Br Med J 1989;299:1187–1190.
Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction: The secondary prevention reinfarction Israel nifedipine trial 2 study. Arch Intern Med 1993;153:345–353.
Muller JE, Morrison J, Stone PH, Rude Re, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo controlled comparison. Circulation 1984;69:740–747.
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109–1113.
Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940–1953.
Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068–1073.
Yusuf S, Held PH, Furberg CD. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67: 1295–1297.
Furberg CD, Psaty BM. Calcium antagonists: Not appropriate as first line antihypertensive agents. Am J Hypertension 1996;9:122–125.
Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–625.
Pahor M, Guralnik JM, Corti M-C, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191–1197.
Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short acting calcium antagonists. In: Laragh J.H. and Brenner, B.M. eds. Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. 1995;2815–2825.
Ruzicka M, Leenen FHH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996;9: 86–94.
Furberg CD, Psaty BM, Meyer JV.Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326–1331.
Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol 1996;27:311–316.
Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, on behalf of the TIBET study group: The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996;17:96–103.
Dargie HJ, Ford I, Fox KM, on behalf of the TIBET study group. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SRS and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104–112.
Neaton JD, Grimm RH, Prineas RJ, Stamler J, et al. Treatment of mild hypertension study. Final results. JAMA 1993;270:713–724.
Aursnes I, Litleskare I, Froyland H, Abdelnoor M: Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Pressure 1995;4: 157–163.
Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by differeing types of antihypertensive therapy. J Hum Hypertens 1992;6:85–90.
Middlemost SJ, Sack M, Davis J, et al. Effects of long-acting nifedipine on casual office blood pressure measurements, 24-hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension. Am J Cardiol 1992;70:474–478.
Fagard R, Lunen P, Staessen J, Thijs L, Amery A. Mechanical and other factors relating to left ventricular hypertrophy. Blood Pressure 1994;3 (Suppl 1):5–10.
Beard K, Bulpitt C, Mascie-Taylor H, O'Malley K, Sever P, Webb S. Management of elderly patients with sustained hypertension. Br Med J 1992;4:412–416.
Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J Hypertens 1995;13:571–579.
Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852–1857.
Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, β-blockers and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481–487.
Olsson G, Tuomilehto J, Berglund G, Elmfeldt D, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertension 1991;4:151–158.
Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993;21:886–893.
Leenen FHH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992;69:639–645.
Lindquist M, Kahan T, Melcher A, et al. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994;24:287–296.
Leenen FHH, Fourney A. Comparison of effects of amlodipine vs. diltiazem on 24 hour blood pressure, plasma catecholamines and left ventricular mass. Am J Cardiol 1996, in press.
Reeves RA, Boer WH, Deleve L, Leenen FHH. Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. Clin Pharmacol Ther 1989;46:279–290.
Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988;116:515–523.
Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993;270:742–744.
Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of β-blockers. JAMA 1990;263: 1653–1657.
Leenen FHH. Therapeutic coverage and end-organ protection in hypertension. Clin Cardiol 1996, in press.
Jicks H, Dervy LE, Gurewich V, Vasilakis C. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996;16:321–326.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leenen, F.H.H. 1,4-Dihydropyridines versus beta-blockers for hypertension: Are either safe for the heart?. Cardiovasc Drug Ther 10, 397–402 (1996). https://doi.org/10.1007/BF00051102
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00051102